Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with neutropenic fever after 4-7 days of broad-spectrum antibiotics are given antifungals empirically. This strategy may lead to over-treatment. METHODS: Patients with hematological malignancies undergoing intensive chemotherapy or hematopoietic stem cell transplantation were randomized to two arms. Patients in the 'preemptive' arm had regular galactomannan (GM) assays, and received caspofungin, amphotericin or voriconazole (CAV) for persistent febrile neutropenia if they had two positive GM results, or a positive GM result and a computed tomography (CT) of the thorax suggestive of invasive pulmonary aspergillosis (IPA). Patients in the 'empirical' arm received CAV in accordance with established guidelines. RESULTS: Of 27 episodes in the preemptive arm, two cases of IPA were picked up by monitoring. In six episodes, CAV was started despite persistently negative GM readings. One additional patient received CAV for a false-positive GM. Of 25 episodes in the empirical arm, CAV was started empirically in 10, one of whom had CT features of IPA. By intent-to-treat and evaluable-episode analyses, respectively, the preemptive approach saved 11% and 14% of patients from empirical antifungals. Twelve-week survival was 85.2% in the preemptive arm and 84% in the empirical arm. CONCLUSIONS: A preemptive approach may reduce empirical antifungal use without compromising survival in persistently febrile neutropenic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Pizzo, P. A., Robichaud, K. J., Gill, F. A., & Witebsky, F. G. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90594-0 · Cited by 859
Use of Procalcitonin to Shorten Antibiotic Treatment Duration in Septic Patients
Nobre, V., Harbarth, S., Graf, J.-D., Rohner, P., & Pugin, J. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200708-1238oc · Cited by 605
Segal, B. H., Almyroudis, N. G., Battiwalla, M., Herbrecht, R., Perfect, J. R., Walsh, T. J., & Wingard, J. R. (2007) · Clinical Infectious Diseases · doi:10.1086/510677 · Cited by 168
Research works printed but not linked: 24
- Marr, 2002, Empirical antifungal therapy—new options, new tradeoffs, N Engl J Med, 346, 278, 10.1056/NEJM200201243460410 · DOI
- EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668–72. · DOI · Paper page
- Rieger, 2008, Empiric vs. preemptive antifungal treatment: an appraisal of treatment strategies in haematological patients, Mycoses, 51, 31, 10.1111/j.1439-0507.2008.01526.x · DOI
- Maertens, 2005, Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study, Clin Infect Dis, 41, 1242, 10.1086/496927 · DOI · Paper page
- de Pauw, 2009, Between over- and undertreatment of invasive fungal disease, Clin Infect Dis, 45, 1251
- Kalil, 2005, Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients, Ann Intern Med, 143, 870, 10.7326/0003-4819-143-12-200512200-00005 · DOI · Paper page
- Jones, 2003, Impact of diagnostic markers on early antifungal therapy, Curr Opin Infect Dis, 16, 521, 10.1097/00001432-200312000-00002 · DOI
- Herbrecht, 2008, Beta-d-glucan detection test: a step towards preemptive therapy for fungal infections in leukemic patients?, Clin Infect Dis, 46, 886, 10.1086/527383 · DOI
- Wong, 2008, Use of antibiotics in a haematology ward—an audit, Ann Acad Med Singapore, 37, 21, 10.47102/annals-acadmedsg.V37N1p21 · doi:10.47102/annals-acadmedsg.v37n1p21
- Ascioglu, 2002, Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus, Clin Infect Dis, 34, 7, 10.1086/323335 · DOI · Paper page
- Maertens, 2008, Early diagnosis and preemptive therapy of pulmonary mold infections in high-risk patients, Curr Infect Dis Rep, 10, 459, 10.1007/s11908-008-0075-y · DOI
- Cordonnier, 2009, Empirical and preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial, Clin Infect Dis, 48, 1042, 10.1086/597395 · DOI · Paper page
- Oshima, 2007, Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients, J Antimicrob Chemother, 60, 350, 10.1093/jac/dkm217 · DOI
- Singh, 2001, Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients, Clin Infect Dis, 32, 742, 10.1086/319225 · DOI
- Konstantinos, 2005, Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials, Br J Haematol, 131, 22, 10.1111/j.1365-2141.2005.05727.x · DOI · Paper page
- Koh, 2002, Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation, Am J Hematol, 71, 260, 10.1002/ajh.10234 · DOI
- Glasmacher, 2006, An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia, J Antimicrob Chemother, 57, 317, 10.1093/jac/dki440 · DOI · Paper page
- Paya, 2002, Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant recipients: a randomized, placebo-controlled trial, J Infect Dis, 185, 854, 10.1086/339449 · DOI
- Tan, 2008, Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world view, Transpl Infect Dis, 10, 325, 10.1111/j.1399-3062.2008.00325.x · doi:10.1111/j.1399-3062.2008.00325.x
- Pfeiffer, 2006, Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis, Clin Infect Dis, 24, 1414
- Marr, 2005, Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay, Clin Infect Dis, 40, 1762, 10.1086/429921 · DOI · Paper page
- Herbrecht, 2002, Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients, J Clin Oncol, 20, 1898, 10.1200/JCO.2002.07.004 · DOI · Paper page
- Siemann, 2001, The Platelia Aspergillus ELISA in diagnosis of invasive pulmonary aspergillosis (IPA), Mycoses, 44, 266
- Ruping, 2008, Patients at high risk of invasive fungal infections, Drugs, 68, 1941, 10.2165/00003495-200868140-00002 · DOI · Paper page
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
“Biomarkers have been evaluated in 2 ways: serial screening of asymptomatic high-risk patients [96, 587, 588] and guiding targeted antifungal therapy for a subset of persistently febrile patients [589, 590].”
BackgroundUllmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Estimation of Direct Healthcare Costs of Fungal Diseases in the United States
Benedict, K., Jackson, B. R., Chiller, T., & Beer, K. D. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy776 · Cited by 438
“When applied in at-risk populations with higher pre-test probabilities of infection, diagnostic-driven strategies like these have reduced costs by 32% [35] and reduced empiric antifungal use by 11–14% as compared with standard empiric strategies [36].”
BackgroundGroll, A. H., Castagnola, E., Cesaro, S., Dalle, J.-H., Engelhard, D., Hope, W., Roilides, E., Styczynski, J., Warris, A., & Lehrnbecher, T. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70017-8 · Cited by 407
Cornely, O. A., Hoenigl, M., Lass‐Flörl, C., Chen, S. C. ‐., Kontoyiannis, D. P., Morrissey, C. O., Thompson, G. R., & for the Mycoses Study Group Education and Research Consortium (MSG‐ERC) and the European Confederation of Medical Mycology (ECMM) (2019) · Mycoses · doi:10.1111/myc.12960 · Cited by 215
ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children
Warris, A., Lehrnbecher, T., Roilides, E., Castagnola, E., Brüggemann, R. J. M., & Groll, A. H. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.05.019 · Cited by 183
Heinz, W. J., Buchheidt, D., Christopeit, M., von Lilienfeld-Toal, M., Cornely, O. A., Einsele, H., Karthaus, M., Link, H., Mahlberg, R., Neumann, S., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3098-3 · Cited by 172
Metadata
- Authors
- Tan, B. H., Low, J. G. H., Chlebicka, N. L., Kurup, A., Cheah, F. K., Lin, R. T. P., Goh, Y. T., & Wong, G. C.
- Venue
- International Journal of Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 15
- Issue
- 5
- Pages
- e350-e356
- ISSN
- 1201-9712 (ISSN-L)
- OpenAlex
- W2012552495
- Cited by
- 58
- References
- 5
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 807 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.